Position of the Transparency Council – Kinpeygo (budesonide)
At its meeting on 26 August 2024, the Transparency Council adopted position No. 86/2024 on the evaluation of the drug Kinpeygo (budesonide) under the new drug program: “Treatment of patients with primary IgA nephropathy (ICD-10: N02.8)”.